The effectiveness of routine outpatient follow up in detecting recurrent disease after 'curative' surgery for breast cancer has been evaluated in a retrospective study of 148 patients. In all, 32 patients developed recurrent cancer. In 3 cases, asymptomatic disease was discovered by routine X-rays. In 25 cases, the patient noticed local disease or complained of symptoms due to distant spread, and over half of these returned to the clinic before the next routine appointment. In only 4 cases was routine examination by a doctor solely responsible for the discovery of recurrent disease. It is concluded that routine follow up made little contribution to the welfare of these patients.
Introduction
Regular follow up after resection of large bowel cancer is of little value because recurrent disease generally remains undetected until it is incurable, and the annual yield of metachronous tumours is low (Cochrane et al. 1980) . It might be expected that breast cancer follow up would be more worthwhile since relatively small local recurrences or metachronous disease can be found by physical examination. To determine if this was so, we examined the records of patients with breast cancer who had had all known disease extirpated by surgery.
Patients and results
The records of all patients who had 'curative' surgery for breast cancer at Edgware General Hospital between 1976 and 1984 were reviewed. There were 148 patients who had negative bone scans and chest X-rays at the time of operation and who had been followed up postoperatively for at least 6 months. The menopausal status and staging of these patients is shown in Table 1 . Treatment: Patey mastectomy was performed in 107 patients, local excision with axillary clearance or sampling in 35, and simple mastectomy in 6. Of these patients, 91 also received local radiotherapy and 13 adjuvant chemotherapy.
Follow up: The mean follow-up period was 32 months (range 6-82 months). Data were collated from the time of operation until the last recorded outpatient visit in disease-free patients or until the presentation of recurrent cancer. The 148 patients made a total of 1098 surgical follow-up visits (mean 7.5 each). Data from radiotherapy and other clinics, apart from the mode of presentation of 4 cases of recurrent cancer, are not included.
Recurrent disease andfalse alarms: Of the 148 patients, 76 remained completely well. On 46 occasions, the remaining patients complained of symptoms which proved to be due to benign causes. On 20 of these occasions, the patients concerned returned to clinic before the next routine appointment. Some 32 patients developed recurrent cancer. Of these, 25 noticed symptoms or signs themselves, and 14 returned early for advice. In 13 instances, signs compatible with locally recurrent disease were found by a clinician in asymptomatic patients at routine follow up; 9 of these cases proved to be benign and 4 malignant. Asymptomatic disseminated disease was found on 3 occasions by routine tests ( 
Discussion
The incidence of local recurrence after simple mastectomy for stage I and II disease at 5 years is 8-35%, depending on the type of operation, the stage of the disease and whether or not patients also receive radiotherapy (International Multicentre Trial 1976 , Atkins et al. 1976 ). After adequate local treatment, recurrent disease usually presents with symptoms due to distant metastases. The 5-year survival of patients with stage I disease is 75% and that of stage II patients is 45% (Brinkley & Haybittle 1975) . The annual death rate thereafter among survivors remains at 5-12% (Langlands et al. 1975 ). The 5-year survival for patients with stage III or IV disease is low, but the late attrition rate, at least among patients with stage III disease, is little worse than that found in patients with early breast cancer. Most studies show that survival figures are not affected by the primary treatment.
Routine follow up is justified if doctors detect recurrent or metachronous disease significantly earlier than do the patients themselves, with a consequent improvement in cure rate or palliation. However, long follow-up intervals reduce the chances of early detection, and it is common for patients to be seen no more than annually by the fourth postoperative year. Furthermore, asymptomatic metastases are seldom discovered by routine bone scans or X-rays (Chaudary et al. 1983) , and it is noteworthy that the incidence of metachronous disease is only 7.6 cases per 1000 patients at risk per annum (Chaudary et al. 1984 ). In the present study, over 40% of patients with recurrent cancer presented between routine appointments and the majority of these had distant metastases. Recurrent cancer was found by clinical examination alone on only 4 out of 1098 outpatient visits. In every other case, except the 3 revealed by routine tests, the patient brought the presence of disease to the attention of the doctor. These findings are in accordance with those of other studies (Clark & Morris 1981 , Broyn & Froyen 1982 . Finally, it must be pointed out that there is no evidence that prompt diagnosis of recurrent cancer improves the prognosis of the patient concerned.
As after any surgical operation, a small number of outpatient visits are likely to be necessary. Thereafter, we believe that routine follow up is of no material benefit to the great majority of patients with resectable disease. Routine follow up should be arranged for those patients who find it reassuring, for those who may have difficulty identifying local recurrences or metachronous disease and possibly for patients at particular risk of developing local recurrence. However, other patients who, after appropriate explanation, prefer to attend 'on demand' are unlikely to come to harm.
